AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

We provide aggregated data on dividend stocks. AbbVie has been named a Top Socially ... Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being ...

By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered ...

Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...

AbbVie holds a strong portfolio of marketed and ... Imbruvica's strong clinical data in several forms of blood cancer led to peak sales above $5 billion, but increasing competition has led to ...